Mtx Ratiophann (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the availability of tetrahydrofolate needed for DNA synthesis. This limits the replication of rapidly dividing cells and also suppresses inflammatory pathways, providing both anti‑cancer and disease‑modifying effects.

The exact dose of methotrexate is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. No universal dosing regimen is provided here.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding as it can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexate is a conventional synthetic DMARD that is often used as first‑line therapy because of its oral and injectable options, extensive clinical experience, and lower cost compared with biologics. Biologic agents target specific cytokines and may be added when methotrexate alone does not achieve disease control.

Store the product at ambient temperature, preferably below 25 °C, in its original container. Protect it from moisture and direct sunlight. Do not freeze. Follow standard aseptic techniques when preparing for injection.

Mtx Ratiophann is supplied as a sterile injectable solution that can be given by epidural, intra‑articular or intramuscular injection, according to the prescribing clinician’s instructions and the therapeutic indication.

Serious risks include severe liver toxicity, pulmonary fibrosis, and profound bone‑marrow suppression that can lead to life‑threatening infections or bleeding. Patients should report persistent cough, jaundice, unusual bruising, or severe fatigue promptly.

Methotrexate should be avoided in pregnant women, individuals with severe liver disease, uncontrolled infections, significant renal impairment, and those with known hypersensitivity to methotrexate or its excipients.